

Preparation of pyridine-stretched 2'-deoxyhypoxanthosine phosphoramidite

Russell Clayton,^a Michael L. Davis,^b Wei Li,^b William Fraser,^{*b} and Christopher A. Ramsden^{*a}

^aLennard-Jones Laboratories, School of Physical and Geographical Sciences, Keele University, Keele, Staffordshire, ST5 5BG, UK

^bSchool of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK
Email: w.fraser@aston.ac.uk, c.a.ramsden@keele.ac.uk

Dedicated to Prof. Oleg A. Rakitin on the occasion of his 65th birthday


Received 02-28-2017

Accepted 03-24-2017

Published on line 04-10-2017

Abstract

Pyridine-stretched 2'-deoxyhypoxanthosine (strH) phosphoramidite was prepared in eight steps from Hoffer's sugar (2'-deoxy-3,5-di-*O*-(*p*-toluoyl)- α -D-erythro-pentofuranosyl chloride). Improved synthesis of the Hoffer sugar was achieved without need for distillation or chromatographic separation of intermediates, or use of gaseous HCl. Conditions were optimised to provide a key nitrile intermediate for the preparation of strH whereby the cesium salt of 4(5)-nitroimidazole was glycosylated using Hoffer's sugar. The nitrile intermediate was also used to prepare pyridine-stretched 2'-deoxyadenosine (strA) and pyridine-stretched 2'-deoxy-2,6-diaminonebulamine (strD). Preliminary studies indicate that strH forms a stronger, size-expanded base pair with adenine compared with the Watson-Crick thymine-adenine base pair.



Keywords: 5-Aminoimidazoles, Hoffer's sugar, pyridine-stretched purines, hypoxanthosine, phosphoramidite

Introduction

The insertion of a third ring between the pyrimidine and imidazole fragments of purine nucleosides has been investigated by several groups. Leonard and co-workers described the earliest synthesis of the benzene-stretched adenosine analogue **1**.¹⁻⁴ Later, the 2'-deoxy derivative **3** was prepared (Figure 1).⁵ Recently, benzo homologation of various nucleosides and their oligomerisation has culminated in the realisation of complete series' of benzene-stretched xDNA⁶⁻⁸ and yDNA⁹ analogues that are orthogonal to natural DNA. The limits to size expansion have continued to be explored through the study of base-pairs formed between purines and their naphtho-homologated complements in "double-wide DNA" (yyDNA).¹⁰ "There remains much to be discovered with such size-expanded genetic sets" according to Kool and co-workers.¹¹ Size-expanded bases are recognised correctly and with efficiency when inserted into *E. coli*¹² and can encode amino acids of a protein in a living organism.¹³ Pyridine-stretched adenine is fluorescent and when incorporated into oligomers as the acyclonucleoside **6** provides a useful probe for the detection of single nucleotide polymorphisms in representative DNA and RNA sequences.¹⁴⁻¹⁶

Results and Discussion

It has been our aim to assess the effect that pyrido homologation has on the base-pairing and molecular recognition properties of size-expanded oligonucleotides. We have previously described the preparation of adenosine analogue **2** and the corresponding xanthosine and hypoxanthosine analogues.¹⁷ Subsequently, we prepared the 2'-deoxynucleoside analogues of adenine **4** (strA) and hypoxanthine **5** (strH).¹⁸ More recently we described the synthesis of various 9-substituted adenine and hypoxanthine derivatives.¹⁹ A key intermediate for the synthesis of strH **5** and related derivatives is the nitrile **24** (Scheme 3). Here we describe the preparation of intermediate **24** and its conversion to the strH nucleoside phosphoramidite **30** for incorporation into oligonucleotides, together with a preliminary study of the base-pairing properties of strH.





Figure 1. The structures of benzene- and pyridine-stretched nucleosides **1** to **5** and acyclonucleoside **6**.

As the starting point for synthesis of the nucleoside intermediate **15**, we selected the well-known and widely used Hoffer sugar (2-deoxy-3,5-di-*O*-(*p*-toluoyl)- α -D-erythro-pentofuranosyl chloride) **10**.²⁰ It is prepared as a single anomer in three steps from 2-deoxy- α/β -D-erythro-pentopyranose **7** (Scheme 1). A typical Hoffer procedure²¹ gives the sugar **10** as a solid that must then be glycosylated otherwise decomposition

occurs on storage beyond two weeks, even under vacuum. Improvements to the original procedure have been made.²²⁻²⁴ We now describe an improved procedure that increases the yield of the sugar **10** and also circumvents the use of gaseous HCl or the need for distillation or chromatographic purification of intermediates.




Scheme 1. The preparation of Hoffer's sugar **10** from 2-deoxy- α/β -D-erythro-pentopyranose **7**.

Thus, acetalation of 2-deoxy- α/β -D-erythro-pentopyranose **7** using methanolic HCl, generated *in situ* by reaction of acetyl chloride with methanol, gave 1-O-methyl-2-deoxy- α/β -D-erythro-pentofuranose **8** in quantitative yield. Esterification of **8** using *p*-toluoyl chloride in pyridine gave **9** as a syrup that, with careful drying, solidified to give **9**, again in quantitative yield. Chlorination of **9** gave the Hoffer sugar **10** as a white solid (67%) using 4M HCl in dioxane. Samples of sugar **10** prepared by this procedure could be stored without discoloration or deterioration.

In previous glycosylations to prepare ribonucleosides, we used the silver salt of the 4(5)-nitroimidazole anion to give a pair of β -anomers, where the required 5 β -regioisomer predominated.¹⁷ We employed the same conditions to carry out glycosylation of the silver salt **11** using the Hoffer sugar **10** in xylene to yield a pair of β -anomers; the required 5-regioisomer **15** was obtained together with the 4-regioisomer **16** in 1:2 ratio (Scheme 2). The required isomer **15** was isolated by flash column chromatography in pure crystalline form. The outcome of glycosylations using **10** is strongly influenced by choice of solvent and nucleophile. When acetonitrile was used instead of xylene, glycosylation gave an almost even distribution of all four possible isomers **15**, **16**, **17** and **18**.

Use of the lithium salt **12** under these reaction conditions resulted in an increased yield of the α -anomers **17** and **18** at the expense of lowered yields of the β -anomers **15** and **16**. Using the sodium salt **13**, generated *in situ* using sodium hydride, before addition of **10**, Bergstrom and co-workers reported isolation of 5 β **15** and 4 β **16** isomers in a ratio of 1:2.²⁵

When we used the preformed sodium salt **13**, glycosylation gave a slight improvement in yield and ratio of β -anomers **15/16** (1:1.5), accompanied by small amounts of the α -anomers **17** and **18**.



Scheme 2. The glycosylation of Hoffer's sugar **10** using the metal salts **11** to **14** of 4(5)-nitroimidazole.

In the absence of an acyloxy substituent at the C2' position, glycosylation is most likely to proceed by an S_N2 Walden inversion process to give the β-configured products. Formation of α-configured nucleosides by a similar process can be explained if the sugar **10** first isomerises. The anomerisation of the α-configured sugar **10** to the more reactive β-anomer is known to occur readily in solvents of higher dielectric constant, and is further enhanced by the presence of lithium, silver and to a lesser extent, sodium ions.^{26,27} During the timescale used for these glycosylation reactions (3 h), we observed by ¹H NMR, that the α-configured sugar **10** underwent 40% inversion to the more reactive β-anomer in acetonitrile-*d*₃ whereas less than 5% inversion occurred in THF-*d*₈. We expected that use of less polar THF for the glycosylation would favour formation of the β-anomers **15** and **16** over the α-anomers **17** and **18**. We reasoned that use of the cesium salt **14** might also lead to an improvement in the anomeric ratio (β/α) as Cs⁺ is less likely to co-ordinate to the substituent at C1' and enhance anomerisation of the α-configured sugar **10**. Glycosylation of cesium salt **15** with sugar **10** for 3 h at 62 °C in THF gave the pure 5-nitro-1'-β-isomer **15** in an isolated yield of 68%. Clearly, the use of the cesium salt **14** not only improves the anomeric ratio but also improves the regioselectivity **15/16** of the reaction.





Figure 2. Selected NOESY correlations for 5-nitro-1'- β -isomer **15**, 4-nitro-1'- β -isomer **19** and 4-nitro-1'- α -isomer **20**.

The identities of all four isomers **15** to **18** were established by ^1H and ^{13}C NMR analysis with 5-nitro-1'- β **15** (triplet, δ 6.72 ppm) and 5-nitro-1'- α (doublet, δ 6.80 ppm) **17** anomeric proton signals being downfield relative to those of the 4-nitro-1'- β **16** (triplet, δ 6.17 ppm) and 4-nitro-1'- α **18** (doublet, δ 6.46 ppm) signals. The positions of carbon signals of 5-nitro-1'- β -isomer **15** (C2 and C4 = 138.13 and 134.33 ppm; C5 not observed) and 4-nitro-1'- β -isomer **16** (C2, C4 and C5 = 134.28, 148.49 and 116.79 ppm) were in agreement with the respective chemical shifts reported for 1-substituted-5- and 1-substituted-4-nitroimidazoles.^{17,28}

The identities of compound **15** and compounds **19** and **20**, which are the deprotected derivatives of isomers **16** and **18**, were further confirmed by NOESY correlations (Figure 2). Removal of the *p*-toluoyl protecting groups from compounds **16** and **18** was achieved using methylamine in methanol to give nucleosides **19** and **20**. Under the same conditions, attempts at deprotection of the 5-nitro-1'- β -isomer **15** failed. The 5-nitro-1'- α -isomer **17** was unavailable in sufficient quantity to attempt deprotection. The 5-nitroimidazole nucleoside **15** was catalytically reduced to give amine **21** that was promptly reacted with ethoxymethylene malononitrile (Scheme 3).



Scheme 3. The preparation of the key nitrile nucleoside intermediate **24**.


Although amine **21** could be characterised by proton NMR analysis (NH_2 , broad singlet, δ 4.01 ppm) it was prone to decomposition. However, it proved convenient to generate the amine **21** from compound **15** for use directly in the next step, when required. Use of ethoxymethylene malononitrile as electrophile gave exclusively the C-addition-elimination product **22** in accord with our previous work with 5-

aminoimidazoles.^{19,29,30} Compound **22** showed a primary amine signal (δ 7.72 ppm) and a single imidazole proton (δ 7.83 ppm).

Cyclisation of compound **22** was achieved by stirring with ion exchange resin to give the protected nitrile nucleoside **23**. Although the pure, protected nitrile nucleoside **23** was isolated and characterised, it was possible to carry out cyclisation of compound **22** and deprotection concomitantly, to give the key nitrile nucleoside intermediate **24**. This product (**24**), formed in two isolation steps from the 4(5)-nitroimidazole cesium salt **14** (Scheme 2), is a key common intermediate for the preparation of other size-expanded nucleosides **4** and **31** (Scheme 6).


Direct glycosylation of the sodium salt of 5-aminoimidazo[4,5-*b*]pyridine-6-carbonitrile (AIPC) **25**³¹ using Hoffer's sugar **10** provided a convergent route to the protected nitrile nucleoside **23** (Scheme 4). The sodium salt of compound **25** was generated *in situ* and a solution (THF) of the sugar **10** was added dropwise (15 min) at 55 °C (2 h) to give a 1:2 mixture of the β -anomers **23** and **26**. The pure compounds **23** (19%) and **26** (22%) were readily isolated after separation by flash column chromatography. When the same reaction was carried out but with the sugar added immediately as a single portion at room temperature (2 h), the anomeric ratio improved giving a near 1:1 mixture of β -anomers **23** and **26** but in lower overall yield. In this case, pure compound **23** (14%) was readily isolated.

Although the direct glycosylation of Hoffer's sugar using AIPC **25** has not been optimised, our preferred route to the key nitrile intermediate is the longer one via nitroimidazole nucleoside **15**. AIPC **25** is readily prepared in high yield (90%)³¹ by a straightforward reaction between purine with malononitrile. However, purine is expensive to source commercially. The simplest and most direct of the various synthetic routes to purine involves heating neat formamide (>160 °C) but the isolated yield (14.4%) of pure product is very modest.^{32,33} It was possible to recover unreacted formamide and subject it to further reaction without deterioration in the yield of purine.



Scheme 4. The preparation of protected nitrile **23** by direct glycosylation of the sodium salt of compound **25** using Hoffer's sugar **10**.


The preparation of amide **27** from nitrile **24** was achieved in 79% yield using H₂O₂ and aq NH₃ or directly from amine **22** in 67% yield by refluxing (3 h) with NaOH in MeOH (Scheme 5). Subsequent cyclisation of the amide **27** using ethyl formate and sodium ethoxide under reflux (2 h) gave strH nucleoside **5** in 94% yield.



Scheme 5. The preparation of strH phosphoramidite **30** from key nitrile nucleoside intermediate **24**.

Nucleoside phosphoramidites containing hypoxanthine have been incorporated into oligonucleotides by automated solid phase synthesis without the need for additional protection of the carbonyl.^{34,35} We therefore anticipated that no protection of the carbonyl in strH **5** would be required. Dimethoxytritylation of strH **5** provided the O5'-protected derivative **28** (61%) that underwent phosphorylation at O3' using compound **29** and standard conditions to give the strH nucleoside phosphoramidite **30** (51%).

Preparation of the key nitrile intermediate **24** also provides the opportunity to make other size-expanded nucleosides (Scheme 6). Thus, compound **24** in hot diethoxymethyl acetate gave the *O*-acetylimidate which, upon treatment with methanolic ammonia, gave the formamidine. Subsequent treatment with aqueous acetic acid and neutralization gave crystalline strA **4** (47%).



Scheme 6. The preparation of pyridine-stretched 2'-deoxy nucleosides **4** (strA) and **31** (strD).

The nitrile nucleoside **24** was converted to strD **31** (45%) in a single step by reaction with guanidine in a steel bomb at 145 °C. The structures of strA **4** and strD **31** were fully supported by spectroscopic and analytical data.

Preliminary investigation showed strH nucleoside phosphoramidite **30** to be compatible with standard, automated solid-supported oligonucleotide synthesis protocols. Variable temperature UV measurements were used to show that replacement strH was capable of forming Watson-Crick base pairs with adenine (A) to give size-expanded structures formed from a purine and tricyclic pyrimidine-stretched purine (Figure 3). When each thymine (T) base in self-complementary DNA oligomer 5'-dATAATATTAT **32** (T_m 28.4 ± 0.5 °C) was replaced by strH (H), a significant increase in duplex stability was observed for 5'-dAHAAHAHHAH **33** (T_m 42.7 ± 0.5 °C) equivalent to +2.9 °C per replacement.




Figure 3. The Watson-Crick A.T base pair and size-expanded A.strH base pair where C_{1'} represents the position of attachment to the sugar-phosphate backbone in DNA oligomers **32** and **33**.

Conclusions

We have established two routes to the key nitrile nucleoside **24** intermediate that allows access to strH **5**, strA **4** and strD **31**; the pyridine-stretched analogues of 2'-deoxy-hypoxanthosine, 2'-deoxy-adenosine and 2,6-diaminonebulamine. The slightly longer route via nitroimidazole nucleoside **24** is preferred as the more convergent route to the protected key nitrile nucleoside **24** relies on AIPC **25** sourced from purine, which is itself expensive and time-consuming to synthesise in suitable quantities. Nucleoside **23** was converted to the phosphoramidite **30** which was found to be compatible with standard, solid-supported methods of automated synthesis. We demonstrated formation of size-expanded A.strH base pairing that is more stable by +2.9 °C per replacement compared with A.T Watson-Crick base pairing.

Experimental Section

General. NMR spectra were recorded on Bruker AC-250, Bruker Avance 400 or Jeol 400 spectrometers with ¹H spectra referenced to TMS, ¹³C spectra referenced to CDCl₃ or DMSO-*d*₆, and ³¹P spectra referenced to 85% H₃PO₄ (aq). Mass spectra were recorded in chemical ionisation (CI) or electrospray ionisation (ES) mode with a Hewlett-Packard HP 5989B MS Engine apparatus using a HP 59987A API-electrospray LC/MS interface. Electron impact ionisation (EI) mass spectra (70eV) were recorded on a AEI MS1Z mass spectrometer. Infrared spectra were recorded using a Mattson Galaxy 2020 FT-IR Spectrophotometer. Ultraviolet spectra were recorded using a Unicam PU8730 Spectrophotometer. Melting points were measured on a Gallenkamp Electrothermal Digital apparatus and are uncorrected. Flash column chromatography was performed using Sorbsil C60 silica using the

method described by Still, Kahn and Mitra.³⁶ Dry column vacuum chromatography was performed with Merck Silica gel 60 (15-40 μm) using the method described by Pedersen and Rosenbohm.³⁷ TLC was carried out on pre-coated Merck 60 F254 aluminium-backed plates and visualized using UV (254 and 360 nm) and vanillin reagent; vanillin (6.0 g), ethanol (250 mL) and conc. sulfuric acid (2 mL). Ethoxymethylene malononitrile (Aldrich) was purified by flash column chromatography eluting with diethyl ether to give a light yellow crystalline solid.

1-O-Methyl-2-deoxy- α/β -D-erythro-pentofuranose (8). To a stirred solution of 2-deoxy- α/β -D-erythro-pentopyranose **7** (40.0 g, 0.30 mol) in methanol (600 mL) a solution of acetyl chloride (1.35 mL, 20 mol) in methanol (70 mL) was added dropwise (20 min) at rt. After further stirring (15 min), Ag_2CO_3 (13.1 g, 47 mmol) was added and stirring continued (20 min). The resulting mixture was filtered through acid-washed celite and the filter cake washed with MeOH (3 x 30 mL). The filtrate plus washings were concentrated under reduced pressure and dried under high vacuum to yield compound **8** (44.1 g, >99%) as a light brown oil composed of a mixture of α/β -anomers. R_f 0.40 (EtOAc-MeOH 4:1). ^1H NMR (250.1 MHz, CDCl_3): δ 1.63, 1.93 and 2.23 (3 x m, 2H, 2- CH_2), 3.20 (s, 1.5H, 1- β - OCH_3), 3.22 (s, 1.5H, 1- α - OCH_3), 3.39, 3.48 and 3.65 (3 x m, 2H, 5- CH_2), 3.89 and 4.08 (2 x m, 1H, 3-CH), 4.63 (m, 1H, 5-OH), 4.88 and 4.94 (2 x m, 1H, 1-CH) 4.83 (d, J 5.0 Hz, 0.5H, 3-OH), 4.98 (d, J 5.0 Hz, 0.5H, 3-OH).

1-O-Methyl-2-deoxy-3,5-di-O-(*p*-toluoyl)- α/β -D-erythro-pentofuranose (9). The pentofuranose **8** (44.0 g, 0.3 mol) was co-evaporated twice with pyridine (2 x 140 mL), and then dissolved in dry pyridine (170 mL) while stirring under an argon atmosphere. The solution was then chilled (ice/ NaCl /water bath) and *p*-toluoyl chloride (100 g, 0.65 mol) was added dropwise (40 min). The resulting pink slurry was allowed to warm to rt and stirring was continued (24 h). The reaction mixture was evaporated under reduced pressure and concentrated under high vacuum. The residue was partitioned between ether (400 mL) and water (400 mL), and the organic layer was washed with 0.5 M HCl (aq) (3 x 200 mL), saturated NaHCO_3 (aq) (3 x 200 mL) and 5% NaCl (aq) (3 x 200 mL). The ether layer was dried (anhyd. MgSO_4), concentrated under reduced pressure and dried under high vacuum to yield compound **9** as a clear, light orange coloured syrup. Further drying under high vacuum on a slowly rotating rotary evaporator caused crystals to slowly form. On further standing the product **9** (114.6 g, >99%) slowly solidified to give a mixture of α/β -anomers as pale buff crystals. Spectroscopic and analytical data were in agreement with the data published previously.²² R_f 0.49 and 0.52 (EtOAc-Hexane 1:2). ^1H NMR (250.1 MHz, CDCl_3): δ 2.40 (m, 8H, 2- CH_2 , 2 x 4-tol- CH_3), 3.36 (s, 1.5H, 1- β - OCH_3), 3.43 (s, 1.5H, 1- α - OCH_3), 4.45 (m, 2H, 5- CH_2), 5.19 (d, J 4.9 Hz, 0.5H, 1- $\text{CH}\alpha$), 5.21 (m, 0.5H, 4-CH), 5.40 (m, 0.5H, 4-CH), 5.61 (m, 0.5H, 1- $\text{CH}\beta$), 7.23 (m, 4H, 3,5-tol-CH), 7.97 (m, 4H, 2,6-tol-CH).

2-Deoxy-3,5-di-O-(*p*-toluoyl)- α -D-erythro-pentofuranosyl chloride (Hoffer's sugar) (10). The pentofuranose **9** (50.0 g, 0.13 mol) was dissolved in glacial acetic acid (150 mL) by stirring at rt for 20 min under an argon atmosphere. The solution was cooled to 10-15 $^\circ\text{C}$ and 4M HCl in dioxane (150 mL, 0.6 mol) was added dropwise (5 min). The pale, straw-coloured solution was seeded with a small amount of compound **10** and stirred briefly until a precipitate started to form. The stirring was stopped and the reaction mixture stood (40 min) with cooling (ice/water). The resultant white slurry was broken up by swirling the flask and filtered rapidly. The filter cake was packed down, washed with cold ether (3 x 30 mL) and dried under high vacuum to give compound **10** (34.1 g, 67%) as a white solid. Spectroscopic and analytical data were in agreement with the data published previously.²² R_f 0.58 (EtOAc-Hexane 1:2). IR (cm^{-1}): 3030, 2951, 1708, 1276, 1178, 1099, 755. ^1H NMR (250.1 MHz, CDCl_3): δ 2.41 (s, 3H, CH_3), 2.42 (s, 3H, CH_3), 2.74 (m, 1H, 2-CH), 2.84 (m, 1H, 2-CH), 4.61 (dd, J 12.1, 4.1 Hz, 1H, 5-CH), 4.66 (dd, J 12.1 Hz, 4.1 Hz, 1H, 5-CH), 4.85 (m, 1H, 4-CH), 5.58 (m, 1H, 3-CH), 6.47 (d, J 4.2 Hz, 1H, 1-CH), 7.24 (d, J 8.3 Hz, 2H, 3,5-tol-CH), 7.26 (d, J 8.3 Hz, 2H, 3,5-tol-CH), 7.90 (d, J 8.3 Hz, 2H, 2,6-

tol-CH), 7.99 (d, *J* 8.3 Hz, 2H, 2,6-tol-CH). ¹³C NMR (62.9 MHz, CDCl₃): δ 21.70 (CH₃), 21.71 (CH₃), 44.54 (2-CH₂), 63.51 (5-CH₂), 73.56 (4-CH), 84.71 (3-CH), 95.3 (1-CH), 126.66 (C), 126.72 (C), 129.19 (CH), 129.21 (CH), 129.63 (CH), 129.88 (CH), 144.07 (C), 144.30 (C), 166.07 (CO), 166.41 (CO). MS (EI): *m/z* (%) 353 (M⁺ – Cl, 1), 252 (1), 216 (32), 136 (38), 119 (100), 91 (78), 81 (100), 65 (28), 53 (25), 39 (19). Anal. Calcd for C₂₁H₂₂ClO₅: C, 64.8; H, 5.41. Found: C, 64.4; H, 5.39.

4(5)-Nitroimidazole silver salt (11). Nitroimidazole (4.52 g, 40 mmol) was dissolved in conc. aq NH₃ (70 mL) to give a clear yellow solution. A solution of silver nitrate (6.8 g, 40 mmol) in water (40 mL) was added dropwise (20 min) with moderate stirring at rt. After further stirring (10 min) the resultant pale yellow precipitate was filtered off, washed well with ethanol and dried under high vacuum to give the product **11** (8.16 g, 93%) as a pale yellow/white chalky powder. mp >300 °C (lit.¹⁷, > 300 °C). ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 7.34 (s, 1H, CH), 7.89 (s, 1H, CH), not observed (CNO₂). MS (CI) *m/z* (%) 112 (M⁺, 100).

4(5)-Nitroimidazole lithium salt (12). A solution of LiOH·H₂O (0.84 g, 20 mmol) in MeOH (10 mL) was added dropwise to a stirred mixture of 4-nitroimidazole (2.26 g, 20 mmol) and MeOH (20 mL) at rt. After stirring (30 min) the clear dark orange solution was evaporated under reduced pressure to give a solid that was dried under high vacuum to give compound **12** (2.33 g, 98%) as an orange/brown solid. mp >300 °C. ¹H NMR (DMSO-*d*₆, 250.1 MHz): δ 7.34 (s, 1H, CH), 7.89 (s, 1H, CH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 127.4 (CH), 142.7 (CH), not observed (CNO₂). MS (CI) *m/z* (%) 112 (M⁺, 100).

4(5)-Nitroimidazole sodium salt (13). A solution of NaOH (1.6 g, 40 mmol) in MeOH (10 mL) was added dropwise to a stirred mixture of 4-nitroimidazole (4.5 g, 40 mmol) and MeOH (40 mL) at rt. After stirring (10 min), a trace of insoluble material was filtered off, the clear yellow solution was evaporated under reduced pressure and the residue recrystallised from EtOH to give compound **13** (4.2 g, 79%) as yellow crystals. mp >300 °C (lit.¹⁷, >300 °C). ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 7.14 (s, 1H, CH), 7.75 (s, 1H, CH). ¹³C NMR (DMSO-*d*₆, 62.9 MHz): δ 131.0 (CH), 145.6 (CH), not observed (CNO₂). MS (CI) *m/z* (%) 112 (M⁺, 100).

4(5)-Nitroimidazole cesium salt (14). Powdered 4-nitroimidazole (15.0 g, 133 mmol) was added to MeOH (150 mL) and stirred at rt. An aqueous solution of CsOH (23.2 mL 50% w/w, 133 mmol) was added dropwise with stirring (30 min). After further stirring (30 min) the clear yellow solution was filtered, evaporated under reduced pressure and dried under high vacuum. Recrystallization of the resulting solid from isopropanol gave compound **14** (27.5 g, 73%) as yellow/orange crystals. mp >300 °C. ¹H NMR (DMSO-*d*₆, 250.1 MHz): δ 7.09 (s, 1H, CH), 7.71 (s, 1H, CH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 132.6 (CH), 146.8 (CH), not observed (CNO₂). MS (CI) *m/z* (%) 112 (M⁺, 100).

1-(2'-Deoxy-3',5'-di-*O*-toluoyl-β-D-ribofuranosyl)-5-nitroimidazole (15). A solution of the sugar **10** (5.0 g, 12.9 mmol) in dry THF (500 mL) was added dropwise (30 min) to a stirred mixture of 4(5)-nitroimidazole cesium salt **14** (3.8 g, 15.5 mmol) and dry THF (500 mL) at 60 °C. After stirring at this temperature (2 h) the reaction mixture was allowed to cool to rt and filtered through celite. The filtrate and washings were evaporated under reduced pressure. The crude mixture of isomers was dissolved in CHCl₃ (50 mL) and loaded onto a flash chromatography column (70 mm ID column, 150 mm silica, packed dry and degassed with a 1:1 mixture of Et₂O and CHCl₃) and eluted with a 1:1 mixture of Et₂O and CHCl₃. Evaporation of the collected fractions and drying under high vacuum gave compound **15** (4.1 g, 68%) as a colourless solid. mp 159-160 °C. *R_f* 0.49 (Et₂O-CHCl₃ 1:1). IR (cm⁻¹) 3030, 2983, 1723, 1528, 1466, 1111, 1092, 752. ¹H NMR (250.1 MHz, CDCl₃): δ 2.42 (s, 3H, CH₃), 2.46 (s, 3H, CH₃), 2.52 (m, 1H, 2'-CHβ), 3.12 (ddd, *J* 14.3, 5.8, 2.8 Hz, 1H, 2'-CHα), 4.74 (m, 3H, 5'-CH₂ and 4'-CH), 5.64 (m, 1H, 3'-CH), 6.72 (t, *J* 6.3 Hz, 1H, 1'-CH), 7.24 (d, *J* 8.3 Hz, 2H, 3,5-tol-CH), 7.30 (d, *J* 8.3 Hz, 2H, 3,5-tol-CH), 7.84 (d, *J* 8.0 Hz, 2H, 2,6-tol-CH), 7.97 (d, *J* 8.0 Hz, 2H, 2,6-tol-CH), 8.05 (d, *J* 1.3 Hz, 1H, 4-CH), 8.11 (d, *J* 1.3 Hz, 1H, 2-CH). ¹³C NMR (62.9 MHz, CDCl₃): δ 21.74 (CH₃), 21.81 (CH₃), 40.90 (2'-CH₂), 63.66 (5'-CH₂), 74.2 (4'-CH), 84.00 (3'-CH), 88.04 (1'-CH), 126.1 (C), 126.2 (C), 129.18 (CH), 129.37 (CH), 129.44 (CH) 129.62 (CH)

134.33 (4-CH), 138.00 (5-CH), 138.13 (2-CH), 144.5 (C), 144.7 (C), 166.0 (CO), 166.1 (CO). MS (EI) m/z (%) 465 (M^+ , 2), 320 (1), 216 (28), 136 (28), 119 (100), 91 (53), 81 (93), 65 (18), 53 (14), 39 (13), 28 (13). Anal. Calcd for $C_{24}H_{23}N_3O_7$: C, 61.9; H, 5.0; N, 9.0. Found: C, 61.7; H, 4.9; N, 8.8. Evaporation of subsequent fractions gave compound **16** (1.2 g, 20%) as a white solid. Analysis as for the following method for preparation of compounds **16** and **18**.

1-(2'-Deoxy-3',5'-di-O-toluoyl- β -D-ribofuranosyl)-4-nitroimidazole (16) and 1-(2'-Deoxy-3',5'-di-O-toluoyl- α -D-ribofuranosyl)-4-nitroimidazole (18). Method A: Sodium hydride 60% in oil (0.61 g, 15.2 mmol) was added to a solution of 4-nitroimidazole **5** (2.0 g, 17.7 mmol) in dry MeCN (40 mL) under argon. After stirring at rt (15 min), Hoffer's sugar **10** (6.0 g, 15.4 mmol) was added and stirring continued (1 h). The reaction mixture was then filtered and the combined filtrate and washings were evaporated under reduced pressure and dried under high vacuum to yield a crude product mixture. Flash chromatography (EtOAc-Hexane 1:1) was used to separate this mixture into the isomeric title compounds **16** (0.82 g, 28%) and **18** (0.47 g, 17%). Analysis as for method B. Method B: The silver salt **11** (4.7 g, 21.2 mmol) and Hoffer's sugar **10** (8.23 g, 21.2 mmol) in xylene (120 mL) were heated under reflux (140 °C) with stirring (6 h). After cooling and standing overnight, the reaction mixture was filtered under reduced pressure and the solid washed well with $CHCl_3$. The filtrate and washings were removed at up to 60 °C under high vacuum to yield the crude reaction mixture. Flash column chromatography (EtOAc-hexanes, 1:1) was used to isolate two isomeric products, which were identified as compounds **16** and **18**. The faster running compound was identified as compound **16** (3.01 g, 31%) as fine colourless crystals. mp 116-117.5 °C. R_f 0.40 (EtOAc-hexanes, 1:1). 1H NMR (250.1 MHz, $CDCl_3$): δ 2.41 (s, 3H, CH_3), 2.44 (s, 3H, CH_3), 2.63 (m, 1H, 2'- $CH\beta$), 2.63 (ddd, J 14.0, 5.5, 2.3 Hz, 1H, 2'- $CH\alpha$), 4.63 (s, 3H, 4'-CH, 5'- CH_2), 5.73 (m, 1H, 3'-CH), 6.17 (dd, J 7.8, 5.6 Hz, 1H, 1'-CH), 7.24 (2 x d, J 8.0 Hz, 4H, 3,5-tol-CH), 7.64 (d, J 1.3 Hz, 1H, 2-CH), 7.91 (d, J 1.3 Hz, 1H, 5-CH), 7.92 (2 x d, J 8.0 Hz, 4H, 2,6-tol-CH). ^{13}C NMR (62.9 MHz, $CDCl_3$): δ 21.74 (CH_3), 21.80 (CH_3), 39.86 (2'- CH_2), 63.58 (5'-CH), 74.65 (3'-CH), 83.82 (4'-CH), 87.27 (1'-CH), 116.79 (5-CH), 126.06 (C), 126.24 (C), 129.40 (CH), 129.53 (CH), 129.67 (CH), 129.80 (CH), 134.28 (2-CH), 144.67 (C), 144.80 (C), 148.49 (4-CNO₂), 165.85 (CO), 166.13 (CO). The slower running compound was isolated and identified as compound **18** (1.34 g, 14%) as an off-white glassy solid. R_f 0.27 (EtOAc-hexanes, 1:1). 1H NMR (250.1 MHz, $CDCl_3$): δ 2.38 (s, 3H, CH_3), 2.41 (s, 3H, CH_3), 2.84-2.99 (2 x m, 2H, 2'- CH_2), 4.53 (s, 2H, 5'- CH_2), 5.01 (dd, J 5.2, 4.2 Hz, 1H, 4'-CH), 5.64 (m, 1H, 3'-CH), 6.46 (d, 1H, J 5.3 Hz, 1'-CH), 7.26 (d, J 8.2 Hz, 2H, 3,5-tol-CH), 7.37 (d, J 8.2 Hz, 2H, 3,5-tol-CH), 7.66 (d, J 8.2 Hz, 2H, 2,6-tol-CH), 7.95 (d, J 8.2 Hz, 2H, 2,6-tol-CH), 8.13 (s, 1H, 2-CH), 8.62 (s, 1H, 5-CH). ^{13}C NMR ($CDCl_3$, 62.9 MHz): δ 21.37 (2 x CH_3), 38.85 (2'- CH_2), 64.20 (5'-CH), 74.99 (3'-CH), 84.36 (4'-CH), 88.35 (1'-CH), 119.53 (5-CH), 126.51 (C), 126.76 (C), 129.38 (CH), 129.42 (CH), 129.59 (CH), 129.61 (CH), 135.72 (2-CH), 144.20 (C), 144.33 (C), 147.47 (4-CNO₂), 165.20 (CO), 165.70 (CO).

1-(2'-Deoxy- β -D-ribofuranosyl)-4-nitroimidazole (19). Aqueous methylamine (40%, 8.0 mL) was added to a solution of compound **16** (0.78 g, 1.7 mmol) in MeOH (30 mL), and the resulting solution was left to stand at rt overnight. The solution was then evaporated under reduced pressure and the residue purified by flash chromatography (EtOAc-MeOH, 9:1) to yield compound **19** (0.34 g, 87%). An analytical sample was obtained by recrystallisation from EtOAc-MeOH (4:1) as a colourless solid. R_f 0.42 (EtOAc-MeOH, 9:1). 1H NMR (400.1 MHz, DMSO- d_6): δ 2.30 (ddd, 1H, 2'- $CH\alpha$), 2.30 (m, 1H, 2'- $CH\beta$), 3.56 (m, 2H, 5'- CH_2), 3.88 (d, 1H, 4'-CH), 4.34 (s, 1H, 3'-CH), 5.08 (t, 1H, 5'-OH), 5.37 (d, 1H, 3'-OH), 6.14 (dd, 1H, 1'-CH), 8.11 (d, 1H, 2-CH), 8.59 (d, 1H, 5-CH). ^{13}C NMR (62.9 MHz, DMSO- d_6): δ 41.45 (2'- CH_2), 61.49 (5'- CH_2), 70.61 (3'-CH), 87.16 (4'-CH), 88.56 (1'-CH), 119.58 (5-CH), 136.26 (2-CH), 147.40 (4-CNO₂).

1-(2'-Deoxy- α -D-ribofuranosyl)-4-nitroimidazole (20). Using aqueous methylamine, compound **20** (1.03 g, 84%), was prepared from compound **18** using the above procedure for the preparation of compound **19** from compound **16**. mp 118.5-119.5 °C. R_f 0.27 (EtOAc-MeOH, 9:1). 1H NMR (400.1 MHz, DMSO- d_6): δ 1.94 (d, 1H,

2'-CH), 2.69 (q, 1H, 2'-CH), 3.43 (m, 2H, 5'-CH₂), 4.16 (s, 1H, 4'-CH), 4.31 (s, 1H, 3'-CH), 4.91 (t, 1H, 5'-OH), 5.52 (s, 1H, 3'-OH), 6.15 (d, 1H, *J* 7.1 Hz, 1'-CH), 8.06 (s, 1H, 2-CH), 8.56 (s, 1H, 5-CH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 41.08 (2'-CH₂), 61.76 (5'-CH₂), 70.83 (3'-CH), 87.95 (4'-CH), 89.83 (1'-CH), 120.01 (5-CH), 136.48 (2CH), 147.36 (4-C).

5-Amino-1-(2'-deoxy-3',5'-di-*O*-*p*-toluoyl-β-D-ribofuranosyl)-imidazole (21). 1-(2'-Deoxy-3',5'-di-*O*-toluoyl-β-D-ribofuranosyl)-4-nitroimidazole **15** (50 mg, 0.11 mmol), 5% Pd on C (50 mg) and THF-*d*₈ (1.0 mL) were vigorously shaken with H₂ at atmospheric pressure and rt. After 2.5 h TLC analysis indicated that no starting material remained. The reaction mixture was filtered through a THF-*d*₈ wetted bed of pre-dried sand and celite, in a Pasteur pipette, using a slight argon pressure into a dry, argon-purged NMR tube. The filter bed was washed with THF-*d*₈ (2 x 0.25 mL). The clear pale yellow solution of compound **21** was analysed immediately by ¹H NMR. *R*_f 0.57 (EtOAc-MeOH-conc. aq NH₃, 10:1:1). ¹H NMR (THF-*d*₈): δ 2.37 (s, 3H), 2.39 (s, 3H, CH₃), 2.55 (ddd, 1H, 2'-CH_α), 2.97 (m, 1H, 2'-CH_β), 4.01 (br s, 2H, NH₂), 4.52 (2 x m, 3H, 5'-CH₂ and 4'-CH), 5.63 (m, 1H, 3'-CH), 6.07 (dd, 1H, *J* 8.9, 5.4 Hz, 1'-CH), 6.15 (s, 1H, 4H), 7.26 (m, 5H, 3,5-tol-CH and 2H), 7.92 (d, 4H, 2,6-tol-CH).

5-Amino-4-(2,2-dicyanovinyl)-1-(2'-deoxy-3',5'-di-*O*-*p*-toluoyl-β-D-ribofuranosyl)-imidazole (22). 1-(2'-Deoxy-3',5'-di-*O*-toluoyl-β-D-ribofuranosyl)-4-nitroimidazole **15** (3.27 g, 7.03 mmol), 5% Pd on C (3.27 g) and dry THF (150 mL) were vigorously shaken with H₂ at atmospheric pressure and rt. After 2 h, a sample was removed and TLC analysis indicated a spot due to compound **21** and no starting material. The reaction flask was evacuated and purged with argon. The product mixture was then filtered through a bed of dry celite (acid washed) in an enclosed system using argon pressure (2 to 4 psi) into a dry, argon-purged receiver flask containing ethoxymethylene malononitrile (1.46 g, 13.52 mmol). The filter bed was washed with dry THF (3 x 20 mL), again using argon pressure, and the washings were combined with the filtered reaction mixture in the receiver flask. The reaction was stirred at 50 °C under argon, overnight to give a dark brown solution. The THF was removed under vacuum at room temperature and chilled ethyl acetate (20 mL) was added to the residue. The product was filtered off and washed with chilled ethyl acetate (2 x 20 mL) to yield compound **22** (1.95 g, 54%) as a yellow solid. mp 194-196 °C. *R*_f 0.73 (EtOAc-MeOH-conc. aq NH₃, 10:1:1). IR (cm⁻¹) 3348, 2924, 2218, 1715, 1586, 1540, 1354, 1283, 1266, 1112, 752 cm⁻¹. ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 2.39 (s, 3H, CH₃), 2.41 (s, 3H, CH₃), 2.72 (m, 1H, 2'-CH_α), 2.86 (m, 1H, 2'-CH_β), 4.53 (m, 3H, 5'-CH₂ and 4'-CH), 5.63 (m, 1H, 3'-CH), 6.09 (dd, 1H, *J* 8.5, 5.7 Hz, 1'-CH), 7.34 (d, *J* 8.3 Hz, 2H, 3,5-tol-CH), 7.38 (d, *J* 8.3 Hz, 2H, 3,5-tol-CH), 7.72 (br s, 2H, NH₂), 7.79 (s, 1H, C=CH), 7.83 (s, 1H, 2-CH), 7.86 (d, *J* 8.3 Hz, 2H, 2,6-tol-CH), 7.95 (d, *J* 8.3 Hz, 2H, 2,6-tol-CH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 21.17 (CH₃), 21.21 (CH₃), 35.88 (2'-CH₂), 58.63 (C(CN)₂), 63.96 (5'-CH₂), 74.72 (4'-CH), 81.69 (3'-CH), 82.81 (1'-CH), 116.20 (4-C), 117.99 (CN), 118.56 (CN), 126.43 (2 x C), 129.29 (CH), 129.38 (CH), 129.50 (CH), 134.21 (2-CH), 143.53 (C=CH), 143.84 (C), 144.08 (C), 150.02 (5-C), 165.12 (CO), 165.40 (CO). MS (ES): *m/z* (%) 511 (M⁺, 7), 353 (7), 159 (41), 119 (68), 91 (23), 81 (100).

5-Amino-6-cyano-3-(2'-deoxy-3',5'-di-*O*-*p*-toluoyl-β-D-ribofuranosyl)-imidazo[4,5-*b*]pyridine (23). Method A. Dowex 1X2-200 ion exchange resin (303 mg) was stirred at 65 °C (3 h) with amine **22** (2.0 g, 3.91 mmol) in acetonitrile (54 mL). The reaction mixture was filtered and the filtrate concentrated under vacuum and dried to give the compound **23** (1.65 g, 83%) as a yellow solid. mp 115-116 °C. *R*_f 0.55 (Et₂O-MeOH 9:1). IR (cm⁻¹) 3347, 3193, 3044, 2947, 2914, 2210, 1712, 1612, 1260, 1166, 1087, 750. ¹H NMR (400.1 MHz, CDCl₃): δ 2.38 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 2.73 (ddd, *J* 14.1, 6.7, 2.5 Hz, 1H, 2'-CH_α), 2.89 (m, 1H, 2'-CH_β), 4.66 (m, 3H, 5'-CH₂ and 4'-CH), 5.80 (br s, 2H, NH₂), 5.35 (m, 1H, 3'-CH), 6.29 (dd, *J* 8.9, 5.5 Hz, 1H, 1'-CH), 7.20 (d, *J* 8.0 Hz, 2H, 3,5-tol-CH), 7.28 (d, *J* 8.0 Hz, 2H, 3,5-tol-CH), 7.80 (d, *J* 8.0 Hz, 2H, 2,6-tol-CH), 7.95 (d, *J* 8.0 Hz, 2H, 2,6-tol-CH), 7.98 (s, 1H, 7-CH), 8.32 (s, 1H, 2-CH). ¹³C NMR (101.6 MHz, CDCl₃): δ 21.72 (CH₃), 21.77 (CH₃), 36.90 (2'-CH₂), 63.83 (5'-CH₂), 75.07 (4'-CH), 82.66 (3'-CH), 84.87 (1'-CH), 87.89 (6-C), 117.73 (CNH₂), 126.43 (C), 126.61 (C),

128.53 (C), 129.30 (2 x CH), 129.65 (CH), 129.79 (CH), 133.89 (2-CH), 144.25 (C), 144.54 (C), 148.05 (C), 156.74 (5-C), 165.93 (CO), 166.36 (CO).

Method B. Sodium hydride 60% in oil (250 mg, 6.3 mmol) was added to a solution of 5-aminoimidazo[4,5-*b*]pyrimidine-6-carbonitrile **25**³¹ (1.0 g, 6.3 mmol) in dry THF (20 mL) under argon with stirring (55 °C). Hoffer's sugar **10** (2.44 g, 6.3 mmol) in THF (25 mL) was then added dropwise (15 min) and stirring continued (2 h). The reaction mixture was filtered, and insoluble salts were washed with THF. The combined filtrate and washings were evaporated under reduced pressure and dried under high vacuum to give the crude product mixture (2.77 g) of compound **23** and isomer **26** (1:2). Flash chromatography (EtOAc-petroleum ether bp 60-80 °C, 2:1) was used to remove faster running impurities then further elution (EtOAc) was used to isolate compound **23** (0.61 g, 18%) as fine yellow needles; analysis as for method A. Further elution (EtOAc-MeOH, 9:1) was used to isolate isomer **26** (0.71 mg, 22%) as a green, glassy solid; mp 107-108 °C; *R_f* 0.22 (EtOAc-MeOH 9:1). IR (cm⁻¹) 3465, 3356, 3199, 3032, 2947, 2913, 2213, 1712, 1606, 1263, 1184, 1093, 753; ¹H NMR (400.1 MHz, CDCl₃): δ 2.39 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 2.73 (ddd, *J* 10.6, 6.1, 2.5 Hz, 1H, 2'-CH α), 3.18 (m, 1H, 2'-CH β), 4.65 (m, 2H, 5'-CH₂), 4.86 (m, 1H, 4'-CH), 5.25 (br s, 2H, NH₂), 5.35 (m, 1H, 3'-CH), 6.43 (dd, *J* 8.0, 7.1 Hz, 1H, 1'-CH), 7.21 (d, *J* 8.1 Hz, 2H, 3,5-tol-CH), 7.27 (d, *J* 8.1 Hz, 2H, 3,5-tol-CH), 7.88 (d, *J* 8.1 Hz, 2H, 2,6-tol-CH), 7.97 (d, *J* 8.1 Hz, 2H, 2,6-tol-CH), 8.03 (s, 1H, 2-CH), 8.04 (s, 1H, 7-CH). ¹³C NMR (101.6 MHz, CDCl₃): δ 21.71 (CH₃), 21.77 (CH₃), 38.90 (2'-CH₂), 63.68 (5'-CH₂), 74.45 (4'-CH), 83.03 (3'-CH), 86.23 (1'-CH), 88.09 (6-C), 118.08 (CN), 126.15 (C), 126.24 (C), 128.53 (C), 129.03 (2-CH), 129.35 (CH), 129.43 (CH), 129.46 (CH), 129.79 (CH), 130.04 (7-CH), 144.46 (C), 144.73 (C), 157.28 (C), 157.70 (C), 165.93 (CO), 166.07 (CO), 175.45 (5-C).

Method C. Sodium hydride 60% in oil (0.25 mg, 6.3 mmol) was added to a solution of 5-aminoimidazo[4,5-*b*]pyridine-6-carbonitrile **25**³¹ (1.0 g, 6.3 mmol) in dry THF (20 mL) under argon. After stirring the mixture at rt (15 min), Hoffer's sugar **10** (2.44 g, 6.3 mmol) was added and stirring continued (2 h). The reaction mixture was filtered, insoluble salts were washed with THF. The combined filtrate and washings were evaporated under reduced pressure and dried under high vacuum to give the crude product mixture (2.77 g) of compound **23** and isomer **26** in near 1:1 ratio, as judged by proton NMR analysis. Flash chromatography (EtOAc-petroleum ether bp 60-80 °C, 2:1) was used to remove faster running impurities then further elution (EtOAc) was used to isolate compound **23** (0.46 g, 14%) as fine yellow needles; analysis as for method A.

5-Amino-6-cyano-3-(2'-deoxy- β -D-ribofuranosyl)-imidazo[4,5-*b*]pyridine (24**).** Method A: Sodium hydroxide (1.0 g, 25 mmol) in water (5.0 mL) was added to a stirred solution of amine **22** (0.4 g, 0.78 mmol) in MeOH (40 mL). The reaction mixture was heated to reflux temperature. After 10 min, TLC analysis indicated no starting material and one main spot was observed that was strongly fluorescent. The reaction mixture was cooled and neutralised to pH 7 using citric acid (20% w/v aq). The mixture was then filtered through a bed of acid-washed filter aid and the filter cake washed well with MeOH. The filtrate and washings were evaporated under reduced pressure. The residue was re-dissolved in warm MeOH, pre-adsorbed on silica and purified by flash chromatography (EtOAc-MeOH-conc. aq NH₃ 15:1:1) to yield compound **24** (0.19 g, 88%) as a light yellow green powder. mp 162-163.5 °C. *R_f* 0.55 (EtOAc-MeOH-conc. aq NH₃, 5:1:1). IR (cm⁻¹) 3337, 3223, 2923, 2216, 1630, 1576, 1432, 1099, 940. ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 2.23 (ddd, *J* 9.0, 7.3, 3.3 Hz, 1H, 2'-CH α), 2.56 (m, 1H, 2'-CH β), 3.52 (m, 2H, 5'-CH₂), 3.82 (m, 1H, 4'-CH), 4.36 (m, 1H, 3'-CH), 4.95 (t, 1H, *J* 5.3 Hz, 5'-OH), 5.31 (d, 1H, *J* 3.5 Hz, 3'-OH), 6.28 (dd, 1H, *J* 7.8, 6.6 Hz, 1'-CH), 6.80 (br s, 2H, NH₂), 8.25 (s, 1H, 7-CH), 8.42 (s, 1H, 2-CH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 39.51 (2'-CH₂), 61.89 (5'-CH₂), 70.99 (4'-CH), 82.71 (3'-CH), 86.26 (6-C), 87.89 (1'-CH), 117.73 (CN), 126.80 (C), 134.37 (2-CH), 141.99 (7-CH), 148.67 (C), 157.55 (5-C). MS (EI) *m/z* (%) 275 (M⁺, 84), 186 (100), 160 (100), 159 (100), 132 (35), 117 (63), 99 (32), 73 (50), 45 (39), 43 (36), 28 (26). HRMS (CI) *m/z* [M⁺ + Na] calcd for C₁₂H₁₃N₅O₃Na: 298.0916. Found: 298.0919.

Method B: Dowex 1X2-200 ion exchange resin (5.2 g) was stirred with aq NaOH (2M, 50 mL) for 30 min. The ion exchange resin was filtered off and washed with de-ionised water until the washings were neutral and then washed with MeOH (2 x 40 mL). Suction was applied for 30 min to dry the resin. The prepared resin was added to amine **22** (2.8 g, 5.5 mmol) and MeOH (50 mL), and the resultant mixture stirred (3 h) at rt. TLC analysis indicated that no starting material was present and only one fluorescent product spot was observed. The reaction mixture was filtered and the resin washed with hot MeOH (5 x 50 mL, 50 to 60 °C). The filtrate and washings were evaporated under reduced pressure and Et₂O (50 mL) was added to the residue. The insoluble material was filtered off, washed with Et₂O (2 x 50 mL) and dried under high vacuum to give compound **22** (1.33 g, 89%) as a light fawn-coloured solid. Analysis as for method A.

5-Amino-3-(2'-deoxy-β-D-ribofuranosyl)-imidazo[4,5-b]pyridine-6-carboxamide (27). Method A: H₂O₂ (2.3 mL, 35% w/w, 23.0 mmol) was added to a stirred mixture of nitrile **24** (0.63 g, 2.3 mmol) in conc. aq NH₃ (25 mL). After stirring at rt (30 min) the solution became clear. TLC analysis after 2 h indicated no starting material and only one product spot. The reaction mixture was partially evaporated under reduced pressure, and after removal of excess NH₃ a precipitate formed. The volume was reduced to ca 10 mL and cooled in the fridge (2 h). The precipitate was filtered off, washed with MeOH (2 x 5 mL) and dried under high vacuum to give compound **27** (0.53 g, 79%) as a very light yellow solid. mp 222-223.5 °C. *R_f* 0.32 (EtOAc-MeOH-conc. aq NH₃, 10:1:1). ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 2.24 (ddd, *J* 10.0, 7.0, 3.0 Hz, 1H, 2'-CHα), 2.65 (m, 1H, 2'-CHβ), 3.55 (m, 2H, 5'-CH₂), 3.84 (m, 1H, 4'-CH), 4.39 (m, 1H, 3'-CH), 5.00 (br s, 1H, 5'-OH), 5.27 (br s, 1H, 3'-OH), 6.31 (dd, 1H, *J* 7.8, 6.0 Hz, 1H-CH), 7.31 (s, 2H, NH₂), 7.90 (br s, 1H, NH), 8.28 (s, 1H, 7-CH), 8.35 (1H, s, 2-CH), 10.20 (br s, 1H, NH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 39.18 (2'-CH₂), 61.89 (5'-CH₂), 70.88 (4'-CH), 82.62 (3'-CH), 87.55 (1'-CH), 105.92 (C), 126.81 (C), 129.48 (2-CH), 140.8 (C), 147.47 (7-CH), 156.94 (C), 170.50 (CO). HRMS (CI): *m/z* [M⁺ + Na] calcd for C₁₂H₁₅N₅O₄Na; 316.1022. Found: 316.1017.

Method B: Sodium hydroxide (3.0 g, 75 mmol) in water (15 mL) was added to MeOH (80 mL) followed by amine **22** (1.2 g, 2.3 mmol) and the mixture refluxed (3 h). TLC analysis (EtOAc-MeOH-conc. NH₃ (aq) 5:1:1) showed compound **23** as a minor component with compound **27** as the major component accompanied by two minor spots of lower *R_f* value. The reaction mixture was cooled, neutralized with citric acid (20% w/v aq) and filtered. The filtrate and MeOH washings were combined and evaporated under reduced pressure. The residue was pre-adsorbed on silica and separated by flash column chromatography (EtOAc-MeOH-conc. aq NH₃, 15:1:1). Residual methyl toluate was removed by sublimation (80 °C, 3 h) under high vacuum. An initial fraction of nitrile **24** (0.20 g, 0.8 mmol) was recovered. The main fraction yielded compound **27** (0.32 g, 67% based on recovered **24**). Analysis as for method A.

3-(2'-Deoxy-β-D-ribofuranosyl)-8H-imidazo[4',5':5,6]-pyrido[2,3-d]pyrimidin-8-one (5). Sodium metal (0.35 g, 15.3 mmol) was dissolved in EtOH (pre-dried over 3Å molecular sieve) (15 mL) under argon. Carboxamide **27** (0.45 g, 1.53 mmol) and ethyl formate (1.1 g, 15.3 mmol) were added and the reaction mixture was stirred (1 h) at 65 °C. TLC analysis indicated no starting material remained. The reaction mixture was cooled and water (20 mL) was added to give a clear colourless solution. Following neutralization with 2M HCl (aq) to pH 7 and upon stirring, the reaction turned cloudy. Stirring was stopped and the reaction mixture placed in the fridge overnight. The precipitate was filtered, washed with water (2 x 5 mL) and MeOH (2 x 5 mL) and then dried under high vacuum to yield compound **5** (400 mg, 85%) as a white chalky solid. The filtrate plus washings were evaporated under reduced pressure. Water (10 mL) was added to the residues and heated to boiling to give a clear solution. On cooling overnight in the fridge a small amount of solid crystallized. Work up as before gave a further crop of compound **5** (444 mg, 94%) as light yellow fine crystals. mp >280 °C. *R_f* 0.15 (EtOAc-MeOH-conc. aq NH₃, 5:2:2). *R_f* 0.66 (MeOH). IR (cm⁻¹) 3504, 3214, 2925, 1686, 1605, 1392, 1235, 1086, 807. ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 2.38 (ddd, *J* 10.0, 5.0, 2.5 Hz, 1H, 2'-CHα), 2.79 (m, 1H, 2'-CHβ), 3.63 (m, 2H, 5'-CH₂),

3.93 (m, 1H, 4'-CH), 4.47 (br s, 1H, 3'-CH), 5.03 (br s, 1H, 5'-OH), 5.35 (br s, 1H, 3'-OH), 6.57 (t, 1H, *J* 7.5 Hz, 1'-CH), 8.29 (s, 1H, 2-H), 8.73 (s, 1H, 6-CH), 8.91, (s, 1H, 9-CH), 12.30 (v br, 1H, NH). ¹³C NMR (62.9 MHz, DMSO-*d*₆): δ 39.31 (2'-CH₂), 61.65 (5'-CH₂), 70.76 (4'-CH), 83.69 (3'-CH), 87.99 (1'-CH), 114.30 (C), 125.94 (CH), 134.71 (C), 147.45 (CH), 147.51 (CH), 150.19 (C), 154.86 (C), 162.01 (CO). MS (FAB): *m/z* (%) 304 (M⁺ + H, 11), 216 (16), 119 (43), 114 (22), 87 (41), 82 (100). HRMS (CI): *m/z* [M⁺ + Na] calcd for C₁₃H₁₃N₅O₄Na; 326.0865. Found: 326.0870.

5'-O-(4,4'-Dimethoxytrityl)-3-(2'-deoxy-β-D-ribofuranosyl)-8H-imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidin-8-one (28). After co-evaporation with dry pyridine (2 x 15 mL), compound **5** (0.36 g, 1.2 mmol) was mixed with dry pyridine (20 mL) and DIPEA (0.5 mL, 40 mmol) under argon. DMTrCl (2.4 g, 7.1 mmol) was added and the reaction mixture stirred at rt. After 1 h all the compound **5** had dissolved to give a clear yellow solution. TLC analysis indicated negligible starting material and three significant fluorescent spots that stained brown with vanillin reagent. The reaction mixture was quenched with MeOH (5 mL) and evaporated under high vacuum using a water bath temperature of 40 °C to give a viscous orange oil. TLC analysis indicated that the fluorescent spot of highest *R_f* value observed prior to evaporation had degraded and two fluorescent spots were observed, the compound with lower *R_f* value being the major product. Following storage overnight at -20 °C, the reaction mixture was separated by dry column vacuum chromatography using gradient elution (5% 2M NH₃-MeOH in EtOAc to 15% 2M NH₃-MeOH in EtOAc) to yield compound **28** and a slower running minor compound that was identified as the ditritylated derivative of compound **28**. The column was further eluted with EtOAc-MeOH-conc. aq NH₃ (10:1:1) to give a small amount of recovered starting material **5** with a further small fraction of compound **28** that was combined with the previous fractions to give compound **28** (0.44 g, 61%) as a colourless solid. mp (decomp.) >150 °C. *R_f* 0.28 (EtOAc-MeOH-conc. aq NH₃, 10:1:1). ¹H NMR (250.1 MHz, DMSO-*d*₆): δ 2.35 (m, 1H, 2'-CH), 2.92 (m, 1H, 2'-CH), 3.25 (m, 2H, 5'-CH₂), 3.35 (s, 3 H, OCH₃), 3.40 (s, 3 H, OCH₃), 4.03 (m, 1H, 4'-CH), 4.52 (br s, 1H, 3'-CH), 5.39 (d, *J* 5.0 Hz, 1H, 3'-OH), 6.57 (t, 1H, *J* 6.7 Hz, 1'-CH), 6.63-7.27 (m, 13 H, Ar), 8.30 (s, 1H, 2-H), 8.70 (s, 1H, 6-CH), 8.80, (s, 1H, 9-CH), 12.50 (br, 1H, NH). ¹³C NMR (250.1 MHz, DMSO-*d*₆): δ 38.50 (2'-CH₂), 54.93 (OCH₃), 54.93 (OCH₃), 64.50 (5'-CH₂), 70.77 (4'-CH), 83.50 (3'-CH), 85.38 (C-Ar₃), 86.50 (1'-CH), 112.9 (CH), 113.0 (CH), 114.50 (C), 126.30 (CH), 126.53 (CH), 127.64 (CH), 129.59 (C), 129.80 (C), 134.90 (CH), 135.52 (C), 135.62 (C), 144.97 (CH), 146.50 (CH), 147.50 (CH), 149.95 (CH), 157.9 (C-OMe), 158.00 (C-OMe), 162.50 (CO). HRMS (CI) [M + Na]⁺ calcd for C₃₄H₃₁N₅O₆Na; 628.2172. Found: 628.2178. Analysis of the ditritylated derivative (*R*¹ = *R*² = DMTr) of compound **28**: HRMS (CI) [M⁺ + Na] calcd for C₅₅H₄₉N₅O₈Na 930.3479. Found: 930.3468.

5'-O-(4,4'-Dimethoxytrityl)-3-(2'-deoxy-β-D-ribofuranosyl)-8H-imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidin-8-one 3'-O-(2-cyanoethyl)-*N,N*-(diisopropyl)-phosphoramidite (30). DIPEA (0.18 g, 1.8 mmol) was added to a solution of compound **28** (0.34 g, 0.56 mmol) in dry THF under argon. 2-Cyanoethyl-*N,N*-diisopropylchlorophosphoramidite **29** (0.18 g, 0.76 mmol) was added and the reaction mixture was stirred at rt (3 h). A precipitate formed and TLC analysis indicated negligible starting material **28** and a new product spot. The reaction mixture was evaporated under reduced pressure and stored over the weekend at -20 °C. The reaction mixture was separated by dry column vacuum chromatography using gradient elution (5% 2M NH₃-MeOH in EtOAc to 15% 2M NH₃-MeOH in EtOAc) to yield the crude title compound **30** (0.34 g, 75%). Purification by repeated (x 7) precipitation of a solution of compound **30** in CH₂Cl₂ (3 mL) using petroleum ether (bp 60-80 °C, 300 mL) gave the pure compound **30** (0.23 g, 51%) as a white powder. *R_f* 0.40 (EtOAc-2M NH₃ in MeOH, 10:1). ¹H NMR (250.1 MHz, DMSO-*d*₆): δ (m, 12 H, 4 x CH₃), 2.67 and 2.77 (dt, 2 H, *J* 26.5, 5.8 Hz, CH₂OP), 2.88 (t, 2 H, *J* 5.9 Hz, CH₂CN), 3.11 (m, 2 H, 2'-CH), 3.18-3.80 (m, 2 H, 2 x NCH), 3.65 (2 x s, 6 H, 2 x CH₃O), 4.05 (m, 2 H, 5'-CH₂), 4.18 (m, 1 H, 4'-CH), 4.79 (m, 1 H, 3'-CH), 6.57 (m, 1H, 1'-CH), 6.75-6.61 (m, 4 H, Ar), 7.10-7.35 (m, 9 H, Ar), 8.30 (s, 1H, 2-CH), 8.71 (s, 1H, 6-CH), 8.83 (s, 1H, 9-CH), 12.48 (br s, 1H, NH). ³¹P

NMR (101.3 MHz, DMSO- d_6): δ 147.8, 148.6. HRMS (CI) m/z [M^+ + Na] calcd for $C_{43}H_{48}N_7O_7Na$: 828.3251. Found 828.3264.

8-Amino-3-(2'-deoxy- β -D-ribofuranosyl)-imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (26). A suspension of compound **24** (100 mg, 0.36 mmol) in excess diethoxymethylacetate (2 mL) was heated to reflux. The reaction was followed by TLC (silica gel, $CHCl_3$ -MeOH, 5:1) and after two hours, there was no starting material present. The excess reagent was removed to give a light brown oil that was redissolved in methanolic ammonia (25 mL) and stirred overnight at rt. The MeOH was removed under reduced pressure and the residue redissolved into 25% aqueous acetic acid (25 mL) and stirred overnight. Following the removal of solvent, water was added (10 mL) and the acidity adjusted to pH 6 with 1M aqueous NaOH. The reaction mixture was then chilled overnight and the precipitate recrystallised from water to give compound **4** (51 mg, 47%) as colourless, needle-like crystals; mp >280 °C. IR (cm^{-1}): 3085, 1684, 1577, 1507, 1419, 1091, 916, 812. 1H NMR (250.1 MHz, DMSO- d_6): δ 2.36 (m, 1H, 2'-CH), 2.83 (m, 1H, 2'-CH), 3.63 (m, 2H, 5'-CH₂), 3.93 (m, 1H, 3'-CH), 4.49 (s, 1H, 5'-OH), 5.15 (t, 1H, *J* 5.6 Hz, 4'-CH), 5.40 (d, 1H, *J* 2.7 Hz, 3'-OH), 6.74 (t, 1H, *J* 6.3 Hz, 1'-CH), 8.09 (br s, 2H, NH₂), 8.51 (s, 1H, 2-CH), 8.92 (1H, s, 6-CH), 9.07 (1H, s, 9-CH). ^{13}C NMR (62.9 MHz, DMSO- d_6): δ 39.44 (2'-CH₂), 61.95 (5'-CH₂), 71.06 (4'-CH), 83.81 (3'-CH), 88.19 (1'-CH), 106.43 (C), 123.80 (CH), 134.68 (C), 148.25 (CH), 151.01 (C), 155.73 (C), 157.87 (CH), 164.11 (C). MS (FAB): m/z (%) 303 (M^+ + H, 53), 187 (31), 165 (30), 152 (46), 124 (36), 120 (46), 115 (35), 107 (100), 105 (43). HRMS (FAB): m/z [M^+ + H] calcd for $C_{13}H_{14}N_6O_3$: 303.1206. Found: 303.1209.

6,8-Diamino-3-(2'-deoxy- β -D-ribofuranosyl)-imidazo[4',5':5,6]pyrido[2,3-*d*]pyrimidine (31). Guanidine hydrochloride (0.40 g, 4.2 mmol) was added to a solution of sodium methoxide (0.23 g, 4.2 mmol) in absolute MeOH (30 mL). The mixture was stirred at 20 °C for 15 min before compound **24** (0.10 g, 0.36 mmol) was added and the mixture stirred at 145 °C for 42 h in a steel bomb after which time TLC analysis (EtOAc-MeOH, 10:1) showed there was no starting material. On cooling, the solid was filtered off and washed successively with water and ethanol to give compound **31** (0.52 g, 45%) as a cream solid; mp >280 °C. IR (cm^{-1}): 3481, 3434, 3318, 3183, 3110, 2887, 1641, 1621, 1470, 1356, 1057, 803. 1H NMR (250.1 MHz, DMSO- d_6): δ 2.23 (m, 1H, 2'-CH), 2.81 (m, 1H, 2'-CH), 3.61 (m, 2H, 5'-CH₂), 3.88 (m, 1H, 4'-CH), 4.44 (m, 1H, 3'-CH), 5.17 (t, 1H, 5'-OH), 5.37 (d, 1H, 3'-OH), 6.19 (br s, 2H, NH₂), 6.42 (t, 1H, *J* 6.5 Hz, 1'-CH), 7.44 (br s, 2H, NH₂), 8.64 (s, 1H, 6-CH), 8.83 (1H, s, 9-CH). ^{13}C NMR (62.9 MHz, DMSO- d_6): δ 39.17 (2'-CH₂), 62.08 (5'-CH₂), 71.17 (4'-CH), 83.84 (3'-CH), 88.01 (1'-CH), 102.19 (C), 123.83 (CH), 131.33 (C), 145.35 (CH), 150.76 (C), 158.27 (CH), 162.78 (C), 164.21 (C). MS (FAB): m/z (%) 318 (M^+ + H, 91), 202 (100), 141 (15), 121 (9). HRMS (FAB) m/z [M^+ + Na] calcd. for $C_{13}H_{15}N_7NaO_3$: 340.1134. Found: 340.1129.

Acknowledgements

We thank Scotia Pharmaceuticals for a studentship (to RC), the Royal Society for a grant (to WF), and the EPSRC Mass Spectrometry Centre for high-resolution mass spectra.

Supplementary Material

Copies of 1H and ^{13}C NMR spectra are provided as supplementary material.

References

1. Leonard, N. J.; Sprecker, M. A.; Morrice, G. A. *J. Am. Chem. Soc.* **1976**, *98*, 3987-3994.
<https://doi.org/10.1021/ja00429a040>
2. Scopes, D. I. C.; Barrio, J. R.; Leonard, N. J. *Science* **1977**, *195*, 296-298.
<https://doi.org/10.1126/science.188137>
3. Leonard, N. J.; Keyser, G. E. *Proc. Natl. Acad. Sci. U.S.A.* **1979**, *76*, 4262-4264.
<https://doi.org/10.1073/pnas.76.9.4262>
4. Leonard, N. J.; *Acc. Chem. Res.* **1982**, *15*, 128-135.
<https://doi.org/10.1021/ar00077a001>
5. Lessor, R. A.; Gibson, K. J.; Leonard, N. J. *Biochemistry* **1984**, *23*, 3868-3873.
<https://doi.org/10.1021/bi00312a012>
6. Liu, H.; Gao, J.; Maynard, L.; Saito Y. D.; Kool, E. T. *J. Am. Chem. Soc.* **2004**, *126*, 1102-1109.
<https://doi.org/10.1021/ja038384r>
7. Gao, J.; Liu, H.; Kool, E. T. *Angew. Chem. Int. Ed.* **2005**, *44*, 3118-3122.
<https://doi.org/10.1002/anie.200500069>
8. Lynch, S. R.; Liu, H.; Gao, J.; Kool, E. T. *J. Am. Chem. Soc.* **2006**, *128*, 14704-14711.
<https://doi.org/10.1021/ja065606n>
9. Lee, A. H. F.; Kool, E. T. *J. Org. Chem.* **2005**, *70*, 132-140.
<https://doi.org/10.1021/jo0483973>
10. Lee, A. H. F.; Kool, E. T. *J. Am. Chem. Soc.* **2006**, *128*, 9219-9230.
<https://doi.org/10.1021/ja0619004>
11. Krueger, A. T.; Lu, H.; Lee, A. H. F.; Kool, E. T. *Acc. Chem. Res.* **2007**, *40*, 141-150.
<https://doi.org/10.1021/ar068200o>
12. Delaney, J. C.; Gao, J.; Lui, H.; Shrivastav, N.; Essigmann, J. M.; Kool, E. T. *Angew. Chem. Int. Ed. Engl.* **2009**, *48*, 4524-4527.
<https://doi.org/10.1002/anie.200805683>
13. Krueger, A. T.; Peterson, L. W.; Chelliserry, J.; Kleinbaum, D. J.; Kool, E. T. *J. Am. Chem. Soc.* **2011**, *133*, 18447-18451.
<https://doi.org/10.1021/ja208025e>
14. Furukawa, K.; Hattori, M.; Ohki, T.; Kitamura, Y.; Kitade, Y.; Ueno, Y. *Bioorg. Med. Chem.* **2012**, *20*, 16-24.
<https://doi.org/10.1016/j.bmc.2011.11.045>
15. Hattori, M.; Ohki, T.; Yanase, E.; Ueno, Y. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 253-257.
<https://doi.org/10.1016/j.bmcl.2011.11.022>
16. Hayai, A.; Maeda, Y.; Ueno, Y. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 3552-3555.
<https://doi.org/10.1016/j.bmcl.2016.06.024>
17. Humphries, M. J.; Ramsden, C. A. *Synthesis* **1999**, 985-992.
<https://doi.org/10.1055/s-1999-3500>
18. Clayton, R.; Davis, M. L.; Fraser, W.; Li, W.; Ramsden, C. A. *Synlett* **2002**, 1483-1486.
<https://doi.org/10.1055/s-2002-33505>
19. Crawford, J. A.; Fraser, W.; Ramsden, C. A. *Synthesis* **2009**, 1271-1278.
<https://doi.org/10.1055/s-0028-10880>
20. Fraser, W. *Adv. Heterocycl. Chem.* **2012**, *107*, 1-39.
<https://doi.org/10.1016/B978-0-12-396532-5.00001-9>

21. Hoffer, M. *Chem. Ber.* **1960**, *93*, 2777-2781.
<https://doi.org/10.1002/cber.19600931204>
22. Chin, T.-M.; Huang, L. K.; Kan, L. J. *Chin. Chem. Soc.* **1997**, *44*, 413-416.
<https://doi.org/10.1002/jccs.199700062>
23. Rolland, V.; Kotera, M.; Lhomme, J.; *Synth. Commun.* **1997**, *27*, 3505-3511.
<https://doi.org/10.1080/00397919708007071>
24. Dhimitruka, I.; SantaLucia Jr., J. *Synlett*, **2004**, 335-337.
25. Bergstrom, D. E.; Zhang, P.; Travis Johnson, W. *Nucleic Acids Res.* **1997**, *25*, 1935-1942.
<https://doi.org/10.1093/nar/25.10.1935>
26. Hubbard, A. J.; Jones, A. S.; Walker, R. T. *Nucleic Acids Res.* **1984**, *12*, 6827-6837.
<https://doi.org/10.1093/nar/12.17.6827>
27. Štimac, A.; Kobe, J. *Carbohydr. Res.* **2000**, *329*, 317-324.
[https://doi.org/10.1016/S0008-6215\(00\)00186-5](https://doi.org/10.1016/S0008-6215(00)00186-5)
28. McKillop, A.; Wright, D. E.; Podmore, M. L.; Chambers, R. K. *Tetrahedron* **1983**, *39*, 3797-3800.
[https://doi.org/10.1016/S0040-4020\(01\)88621-X](https://doi.org/10.1016/S0040-4020(01)88621-X)
29. Al-Shaar, A. H. M.; Gilmour, D. W.; Lythgoe, D. J.; McClenaghan, I.; Ramsden, C. A. *J. Chem. Soc. Perkin Trans. 1*, **1992**, 2779-2788.
<https://doi.org/10.1039/p19920002779>
30. Al-Shaar, A. H. M.; Chambers, R. K.; Gilmour, D. W.; Lythgoe, D. J.; McClenaghan, I.; Ramsden, C. A. *J. Chem. Soc. Perkin Trans. 1*, **1992**, 2789-2811.
<https://doi.org/10.1039/P19920002789>
31. Harris, P. A.; Pendergast, W. J. *Heterocyclic Chem.* **1996**, *33*, 319-322.
<https://doi.org/10.1002/jhet.5570330218>
32. Yamada, H.; Okamoto, T. *Chem. Pharm. Bull.* **1972**, *20*, 623-624.
<https://doi.org/10.1248/cpb.20.623>
33. Saladino, R.; Crestini, C.; Castanzo, G.; Negri, R.; Di Mauro, E. *Bioorg. Med. Chem. Lett.* **2001**, *9*, 1249-1253.
[https://doi.org/10.1016/S0968-0896\(00\)00340-0](https://doi.org/10.1016/S0968-0896(00)00340-0)
34. Marfut, J.; Parel, S. P.; Leumann, C. J. *Nucleic Acids Res.* **1997**, *25*, 1875-1882.
<https://doi.org/10.1093/nar/25.10.1875>
35. Groebke, K.; Hunziker, J.; Fraser, W.; Peng, L.; Diederichsen, U.; Zimmermann, K.; Holzner, A.; Leumann, C.; Eschenmoser, A. *Helv. Chim. Acta* **1998**, *81*, 375-474.
<https://doi.org/10.1002/hlca.19980810302>
36. Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, *43*, 2923-2925.
<https://doi.org/10.1021/jo00408a041>
37. Pedersen, D. S.; Rosenbohm, C. *Synthesis* **2001**, 2431-2434.
<https://doi.org/10.1055/s-2001-18722>